Friday, March 13, 2020

QUACK, QUACK
Indonesia’s President Stokes Speculation Herbs Can Fight Virus
Yoga Rusmana Bloomberg March 12, 2020
(Bloomberg) -- Indonesia’s President Joko Widodo has been bolstering speculation that a herb concoction can ward against being infected with the coronavirus.

Jokowi, as the president is more commonly known, said in a statement posted on a government website that he’s been drinking a mixture of red ginger, lemongrass, turmeric and curcuma, a type of tumeric native to Southeast Asia, three times a day since the spread of the virus.

“I drink the mixture instead of tea now,” Jokowi said in the statement. “I give the drinks to my guests, be it the morning, afternoon or evening.”

The brew is called Jamu, and is widely used as a herbal medicine in Indonesia on claims that it can cure various diseases, from the common flu and stomach aches to uric acid. It’s even believed to increase sexual stamina for men. Industries are built around it and listed companies, such as PT Industri Jamu dan Farmasi Sido Muncul, produce it.

However, its use as a deterrent against the coronavirus are yet to be proven.

Despite this, Jokowi isn’t the only one who’s turned to the herb mixture amid growing fears over the virus. Demand for the blend has risen so much that prices of red ginger, turmeric and curcuma jumped fivefold, the president said. Citizens should take it upon themselves to grow the herbs themselves, he said.

Within more conventional medicine, investors have been placing bets on who will be the first to develop an antiviral for the novel coronavirus. Shares of U.S. drugmakers and biotech companies have been defying a market rout, though there is no treatment or vaccine as yet.

The World Health Organization declared the coronavirus a pandemic as the disease, officially named Covid-19, has spread to 110 countries and regions, killing more than 4,700 people and infecting over 128,000 globally. Indonesia reported its first death this week, while the number of confirmed cases reached 34.


©2020 Bloomberg L.P.

No comments: